EP185: How to Be Patient-centric, Not Clinical Trial–centric, With Pablo Graiver, CEO and Founder of Antidote

Since 2010, under Pablo's leadership, Antidote has raised $26 million in venture capital and grown to become a leading player within the digital health sector, empowering thousands of patients worldwide to discover and access potential new treatment options through clinical trials.

Pablo is a seasoned entrepreneur and manager of internet companies. He’s been building high-scale businesses in online retail, travel, mobile, media, and now health sectors since the late 1990s, including firms such as NetJuice, DondeComprar.com, Kelkoo (acquired by Yahoo!), Kayak (acquired by Priceline), and ValueClick (acquired by Conversant).

Pablo has spoken about technology, health care, and innovation at Harvard Medical School, DIA, Disruptive Innovations, Health 2.0, Digital Health Forum, and many others. He has been included in the “100 Club” by SVC2UK and the “Ones to Watch” list by The Sunday Times's Tech Track 100 and was recently named one of MM&M’s Healthcare Transformers of 2018. He’s also been featured in Wired, the Financial Times, and Forbes; on CNBC, TechCrunch, and Re/code; and more.

Tou can sign up for the Antidote platform by going to antidote.me. You can also learn more by emailing hello@antidote.me.